Valuation: Perspective Therapeutics, Inc.

Market Cap 38Cr 34Cr 31Cr 29Cr 54Cr 3.67TCr 56Cr 373.58Cr 145.16Cr 1.8TCr 144.12Cr 140.96Cr 6.24TCr P/E 2026 *
-3.08x
P/E 2027 * -3.02x
Enterprise Value 20Cr 17Cr 16Cr 15Cr 28Cr 1.88TCr 28Cr 191.43Cr 74Cr 921.43Cr 74Cr 72Cr 3.2TCr EV / Sales 2026 *
471x
EV / Sales 2027 * 147x
Free-Float
89.19%
Yield 2026 *
-
Yield 2027 * -
1 day-0.44%
1 week-1.01%
Current month+0.44%
1 month+16.89%
3 months-21.62%
6 months+21.89%
Current year+24.55%
1 week 3.33
Extreme 3.33
3.78
1 month 2.85
Extreme 2.85
3.78
Current year 2.25
Extreme 2.25
6.16
1 year 1.96
Extreme 1.955
6.16
3 years 1.6
Extreme 1.6
19.05
5 years 1.6
Extreme 1.6
19.05
10 years 1.6
Extreme 1.6
28.1
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2023
Director of Finance/CFO 59 04/09/2025
Chief Tech/Sci/R&D Officer - 01/04/2022
Director TitleAgeSince
Director/Board Member 54 05/02/2023
Chairman 63 03/02/2023
Director/Board Member 60 05/02/2023
Date Insider Type Main position Quantity % Market Cap.
02/03Free

Chief Technology Officer

1,50,000 0.1317%
02/03Free

Director

50,000 0.0439%
02/03Free

Director

50,000 0.0439%
Change 5-day change 1-year change 3-year change Capi.($)
-0.44%-1.01%-2.97%-45.63% 39Cr
-0.24%+1.85%+3.13%+8.40% 4.97TCr
-0.39%+1.18%+420.66%+597.28% 4.05TCr
-2.88%+3.57%+23.18%+56.41% 3.43TCr
-2.30%+0.15%+23.73%-7.26% 3.48TCr
-0.79%+2.02%+3.83%+36.42% 2.7TCr
+2.88%+2.62% - - 1.66TCr
-3.08%-2.49%+64.35%+119.21% 1.56TCr
-2.32%+6.73%+104.45%+102.30% 1.43TCr
-2.70%-2.04%+12.37%+17.77% 1.38TCr
Average -1.34%+3.62%+72.52%+98.32% 2.47TCr
Weighted average by Cap. -1.45%+4.36%+93.67%+133.79%

Financials

2026 *2027 *
Net sales 4L 4L 3L 3L 6L 4Cr 6L 40.67L 15.8L 1.96Cr 15.69L 15.34L 6.8Cr 5L 4L 4L 4L 7L 4.67Cr 7L 47.46L 18.44L 2.28Cr 18.31L 17.91L 7.93Cr
Net income -12Cr -11Cr -9.8Cr -9.05Cr -17Cr -1.16TCr -18Cr -117.76Cr -46Cr -566.82Cr -45Cr -44Cr -1.97TCr -14Cr -12Cr -11Cr -10Cr -20Cr -1.32TCr -20Cr -134.48Cr -52Cr -647.33Cr -52Cr -51Cr -2.25TCr
Net Debt -19Cr -16Cr -15Cr -14Cr -27Cr -1.79TCr -27Cr -182.16Cr -71Cr -876.8Cr -70Cr -69Cr -3.04TCr -31Cr -27Cr -25Cr -23Cr -44Cr -2.99TCr -45Cr -304.02Cr -118.13Cr -1.46TCr -117.28Cr -114.71Cr -5.08TCr
Logo Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Employees
165
Date Price Change Volume
09/26/09 $3.405 -0.44% 12,76,054
07/26/07 $3.420 -5.26% 18,80,308
06/26/06 $3.610 -0.55% 13,45,671
02/26/02 $3.630 +4.91% 15,91,089
01/26/01 $3.460 +1.47% 17,22,445
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
3.420USD
Average target price
12.93USD
Spread / Average Target
+278.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CATX Stock